Alligator Bioscience announces that the exercise period for warrants series TO 13 ended on September 15, 2025. A total of 9 warrants were exercised to subscribe for 009 new ordinary shares, corresponding to an exercise rate of approximately 774 percent. The exercise will provide the company with gross proceeds of approximately SEK 000 million. The number of shares will increase from 9 to 009 shares.
|
Published September 17, 2025
Alligator Bioscience reports 92 percent utilization rate for TO 13
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account